Diamond Equity Predicts MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Diamond Equity issued their Q1 2027 earnings estimates for shares of MAIA Biotechnology in a research report issued to clients and investors on Monday, May 18th. Diamond Equity analyst H. Diamond forecasts that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($0.69) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.46) EPS.

MAIA Biotechnology Stock Performance

NYSEAMERICAN:MAIA opened at $1.26 on Tuesday. The stock has a 50-day simple moving average of $1.37 and a two-hundred day simple moving average of $1.51. The firm has a market capitalization of $76.61 million, a PE ratio of -1.88 and a beta of 0.21. MAIA Biotechnology has a 52-week low of $0.87 and a 52-week high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the 2nd quarter worth approximately $29,000. Ritholtz Wealth Management bought a new position in shares of MAIA Biotechnology in the fourth quarter worth approximately $35,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology in the second quarter worth approximately $52,000. Corsair Capital Management L.P. purchased a new stake in shares of MAIA Biotechnology in the first quarter worth $140,000. Finally, Geode Capital Management LLC increased its stake in shares of MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after purchasing an additional 7,746 shares in the last quarter. 5.65% of the stock is currently owned by institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.